세계의 종합 대사 패널(CMP) 검사 시장 보고서(2025년)
Comprehensive Metabolic Panel (CMP) Testing Global Market Report 2025
상품코드 : 1824362
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

종합 대사 패널(CMP) 검사 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.1%를 나타내 259억 5,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 개인화 및 정밀의료, 원격의료서비스에서의 CMP검사 통합, 종합적인 건강진단 수요, 웰니스 및 예방의료 이니셔티브 증가, 진화하는 헬스케어 정책과 정책에 기인하고 있습니다. 예측 기간의 주요 동향으로는 지속적인 모니터링 및 종단 추적, 원격 의료에 적합한 보고 형식, 표준 범위 표준화, 웨어러블 건강 기술 통합, 환자 교육 및 참여의 중요성 등이 있습니다.

향후 5년간의 성장률 9.1%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 상승은 일본과 아일랜드에서 조달하는 자동화학분석장치와 전해질검사시약의 비용을 밀어 올리고, 루틴의 스크리닝 비용을 악화시켜, 중환자 치료의 결과를 늦추는 것으로, 미국의 검사 시설에 부담을 줄 가능성이 높습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

심혈관 질환과 당뇨병의 유병률 증가가 예상되는 것이 종합 대사 패널(CMP) 검사 시장 성장의 원동력이 될 것으로 예측됩니다. 심장과 혈관에 영향을 미치는 심혈관 질환은 종종 동맥 경화(동맥 내 지방 침착물의 축적)와 관련이 있습니다. 동시에, 증가된 혈당 수치를 특징으로 하는 당뇨병은 종합 대사 패널(CMP) 혈액 검사에 의해 확인될 수 있습니다. 당뇨병과 심혈관 질환의 증례가 증가함에 따라 CMP 혈액 검사를 포함한 진단용 혈액 검사에 대한 수요가 급증할 것으로 보입니다. 예를 들어, 호주 보건복지연구소가 제공한 2023년 12월 데이터는 관상동맥성 심장병(CHD)으로 인한 의사 인증 사망자 수 증가 추세를 보였으며, 2022년에는 1만 4,900명에 달했습니다. 게다가 2022년 6월 국제 당뇨병 연합은 세계 당뇨병 유병률이 10.5%를 나타내 개인의 상당 부분(44.7%)이 진단되지 않은 상태로 보고했습니다. 그 결과, 심혈관 질환과 당뇨병의 이환율 증가가 종합 대사 패널(CMP) 검사 시장을 촉진하는 주요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

A comprehensive metabolic panel (CMP) test is a blood analysis consisting of 14 distinct parameters that provide crucial insights into the body's chemical balance and metabolic processes. This test serves as a vital tool for evaluating nutritional levels, liver and kidney functionality, and aids in diagnosing, screening, and monitoring various health conditions.

The primary diseases and health conditions assessed through comprehensive metabolic panel (CMP) testing include kidney disease, liver disease, diabetes, and other metabolic disorders. Kidney disease is characterized by impaired kidney function, affecting its ability to effectively filter blood and perform essential functions. The test encompasses evaluations of proteins, electrolytes, kidney function, liver function, and glucose levels, conducted in both laboratory settings and point-of-care (PoC) environments.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The comprehensive metabolic panel (CMP) testing market research report is one of a series of new reports from The Business Research Company that provides comprehensive metabolic panel (CMP) testing market statistics, including comprehensive metabolic panel (CMP) testing industry global market size, regional shares, competitors with a comprehensive metabolic panel (CMP) testing market share, detailed comprehensive metabolic panel (CMP) testing market segments, market trends and opportunities, and any further data you may need to thrive in the comprehensive metabolic panel (CMP) testing industry. This comprehensive metabolic panel (CMP) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The comprehensive metabolic panel (cmp) testing market size has grown strongly in recent years. It will grow from $17.04 billion in 2024 to $18.34 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to a rise in chronic diseases, demand for holistic health assessments, healthcare system emphasis on preventive care, rise in lifestyle-related conditions, and patient-centric healthcare approach.

The comprehensive metabolic panel (cmp) testing market size is expected to see strong growth in the next few years. It will grow to $25.95 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to personalized medicine and precision healthcare, integration of CMP testing in telehealth services, demand for comprehensive health screenings, rise in wellness and preventive health initiatives, and evolving healthcare policies and regulations. Major trends in the forecast period include continuous monitoring and longitudinal tracking, telemedicine-friendly reporting formats, standardization of reference ranges, integration of wearable health technology, and emphasis on patient education and engagement.

The forecast of 9.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. laboratories by driving up the cost of automated chemistry analyzers and electrolyte testing reagents sourced from Japan and Ireland, exacerbating routine screening costs and delaying critical care results. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the prevalence of cardiovascular diseases and diabetes is expected to be a driving force behind the growth of the comprehensive metabolic panel (CMP) testing market. Cardiovascular diseases, which affect the heart and blood vessels, are often associated with atherosclerosis-the accumulation of fatty deposits within arteries. Concurrently, diabetes, characterized by elevated blood glucose levels, can be identified through comprehensive metabolic panel (CMP) blood tests. As cases of diabetes and cardiovascular diseases increase, the demand for diagnostic blood tests, including the CMP blood test, is likely to surge. For instance, data from December 2023 provided by the Australian Institute of Health and Welfare indicated a rising trend in doctor-certified fatalities attributed to coronary heart disease (CHD), reaching 14,900 in 2022. Additionally, in June 2022, the International Diabetes Federation reported a global diabetes prevalence of 10.5%, with a significant portion (44.7%) of individuals remaining undiagnosed. Consequently, the growing incidence of cardiovascular diseases and diabetes is a key driver propelling the comprehensive metabolic panel (CMP) testing market.

The growing geriatric population is expected to drive the expansion of the comprehensive metabolic panel (CMP) testing market in the coming years. The term "geriatric population" refers to individuals who are elderly, typically defined as those aged 65 or older. Due to their advanced age, older individuals generally require more frequent health screenings, including metabolic panel testing, to monitor their well-being and address age-related issues. CMP testing is essential for the elderly, helping to detect underlying conditions like kidney disease, hormonal imbalances, and diabetes. For instance, in July 2024, according to the UK Parliament, a UK-based governing body, 12.7 million people in the UK were aged 65 or older in 2022 (accounting for 19% of the population), and by 2072, this figure is projected to increase to 22.1 million, or 27% of the population. Thus, the rising geriatric population is fueling the growth of the CMP testing market.

The comprehensive metabolic panel (CMP) testing market is witnessing a significant trend of technological advancements, with major companies investing in innovative solutions to fortify their market positions. In April 2022, HealthifyMe, an Indian wellness and fitness services company, introduced HealthifyPro, a flagship fitness plan incorporating a metabolic panel based on a comprehensive blood test measuring over 80 different factors. HealthifyPro utilizes a biosensor system, a smart scale, health coaches, an AI assistant, and a metabolic panel to track users' health. The integration of glucose patterns, dietary habits, and exercise behaviors enables the creation of personalized health approaches for each user, showcasing the role of technology in advancing metabolic panel testing.

Strategic partnerships are a prominent approach adopted by major companies in the comprehensive metabolic panel (CMP) testing market. These partnerships aim to enhance production capabilities, streamline testing processes, and meet the increasing demand for CMP testing across various industries. In August 2022, Abbott Laboratories, a US-based healthcare company, collaborated with WW International Inc., a provider of weight loss and fitness services. The partnership focuses on assisting individuals with diabetes in better understanding and managing their health. By integrating WeightWatchers' diabetes-specific weight management program with Abbott's FreeStyle Libre offerings, the collaboration aims to provide a seamless mobile experience, offering valuable insights for individuals with diabetes to make informed dietary adjustments and improve blood sugar levels, ultimately empowering them to take control of their health.

In March 2023, Fluxery, a medical diagnostic company headquartered in the United States, completed the acquisition of particular personnel, assets, and licensed electrochemical biosensing technologies from InnaMed Inc. The financial details of the transaction remain undisclosed. This strategic acquisition by Fluxery significantly expands its detection capabilities, allowing for the analysis of clinical chemistry and small molecules in various domains, including human healthcare, equine care, and veterinary services for small animals. InnaMed Inc., a decentralized blood testing company in the US, specializes in electrochemical biosensor technology.

Major companies operating in the comprehensive metabolic panel (CMP) testing market include Abbott Laboratories Inc., Siemens Healthineers AG, Mayo Clinic, Laboratory Corporation of America Holdings, Mercy, Mount Sinai Health System, Quest Diagnostics Incorporated, Sonic Healthcare Limited, Hologic Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Werfen SA, DiaSorin S.p.A., Randox Laboratories Ltd., ARUP Laboratories Inc., Invitae Corporation, Abaxis Inc., Metropolis Healthcare Limited, Clinical Reference Laboratory (CRL), Centogene AG, Spectra Laboratories, Unipath Systems Ltd., Scion Lab Services LLC, Weldon Biotech Pvt Ltd., Corona Pathology,Ulta Lab Tests LLC, Any Lab Test Now, Applied InGENuity Diagnostics LLC, Walk-In Lab LLC

North America was the largest region in the comprehensive metabolic panel (CMP) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the comprehensive metabolic panel (cmp) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the comprehensive metabolic panel (cmp) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The comprehensive metabolic panel (CMP) testing market includes revenues earned by entities by providing glucose tests, sodium tests, and albumin tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Comprehensive Metabolic Panel (CMP) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on comprehensive metabolic panel (cmp) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for comprehensive metabolic panel (cmp) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The comprehensive metabolic panel (cmp) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Comprehensive Metabolic Panel (CMP) Testing Market Characteristics

3. Comprehensive Metabolic Panel (CMP) Testing Market Trends And Strategies

4. Comprehensive Metabolic Panel (CMP) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Comprehensive Metabolic Panel (CMP) Testing Growth Analysis And Strategic Analysis Framework

6. Comprehensive Metabolic Panel (CMP) Testing Market Segmentation

7. Comprehensive Metabolic Panel (CMP) Testing Market Regional And Country Analysis

8. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market

9. China Comprehensive Metabolic Panel (CMP) Testing Market

10. India Comprehensive Metabolic Panel (CMP) Testing Market

11. Japan Comprehensive Metabolic Panel (CMP) Testing Market

12. Australia Comprehensive Metabolic Panel (CMP) Testing Market

13. Indonesia Comprehensive Metabolic Panel (CMP) Testing Market

14. South Korea Comprehensive Metabolic Panel (CMP) Testing Market

15. Western Europe Comprehensive Metabolic Panel (CMP) Testing Market

16. UK Comprehensive Metabolic Panel (CMP) Testing Market

17. Germany Comprehensive Metabolic Panel (CMP) Testing Market

18. France Comprehensive Metabolic Panel (CMP) Testing Market

19. Italy Comprehensive Metabolic Panel (CMP) Testing Market

20. Spain Comprehensive Metabolic Panel (CMP) Testing Market

21. Eastern Europe Comprehensive Metabolic Panel (CMP) Testing Market

22. Russia Comprehensive Metabolic Panel (CMP) Testing Market

23. North America Comprehensive Metabolic Panel (CMP) Testing Market

24. USA Comprehensive Metabolic Panel (CMP) Testing Market

25. Canada Comprehensive Metabolic Panel (CMP) Testing Market

26. South America Comprehensive Metabolic Panel (CMP) Testing Market

27. Brazil Comprehensive Metabolic Panel (CMP) Testing Market

28. Middle East Comprehensive Metabolic Panel (CMP) Testing Market

29. Africa Comprehensive Metabolic Panel (CMP) Testing Market

30. Comprehensive Metabolic Panel (CMP) Testing Market Competitive Landscape And Company Profiles

31. Comprehensive Metabolic Panel (CMP) Testing Market Other Major And Innovative Companies

32. Global Comprehensive Metabolic Panel (CMP) Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Comprehensive Metabolic Panel (CMP) Testing Market

34. Recent Developments In The Comprehensive Metabolic Panel (CMP) Testing Market

35. Comprehensive Metabolic Panel (CMP) Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기